The safety and efficacy of IFN-β products for the treatment of multiple sclerosis
Authors:
- Sarah MorrowSMSarah Morrow
- Carolina RushCRCarolina Rush
- 4 May 2007
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 6 (3) , 279-288
Abstract
Multiple sclerosis, a chronic demyelinating disease of the CNS, is now a treatable disease. Phase III clinical trials of three recombinant IFN-β products conducted in relapsing-remitting multiple sclerosis have shown, albeit modest, significant effects on relapses and short-term progression of disability, and a more substantial effect on MRI parameters. However, these effects do not correlate well with clinical disease activity or long-term disability. Overall, IFN-β is safe and generally well tolerated, and reported adverse events were comparable between preparations. Systemic side effects can be effectively managed by dose escalation, use of an auto-injector and careful clinical monitoring.Keywords
This publication has 70 references indexed in Scilit:
- Diagnosis and disease modifying treatments in multiple sclerosis2005
- Subcutaneous Recombinant Interferon-??-1a (Rebif??)Drugs, 2005
- Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosisJournal of Neurology, Neurosurgery & Psychiatry, 2004
- Thyroid autoimmunity and dysfunction associated with type I interferon therapyClinical and Experimental Medicine, 2004
- Haematological Effects of Interferon-??-1a (Rebif??) Therapy in Multiple SclerosisDrug Safety, 2004
- Hepatic Reactions During Treatment of Multiple Sclerosis with Interferon-??-1aDrug Safety, 2003
- Aplastic Anemia Associated With Interferon ??-1aAmerican Journal of Therapeutics, 2002
- Granulomatous dermatitis with focal sarcoidal features associated with recombinant interferon β-1b injectionsJournal of the American Academy of Dermatology, 1998
- Axonal Transection in the Lesions of Multiple SclerosisNew England Journal of Medicine, 1998
- Rating neurologic impairment in multiple sclerosisNeurology, 1983